Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial
Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLOS ONE 2021, 16: e0256338. PMID: 34411158, PMCID: PMC8376053, DOI: 10.1371/journal.pone.0256338.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionPrior stroke/TIAStroke/TIASystemic embolismAtrial fibrillationMajor bleedingRE-LYOlder patientsLong-Term Anticoagulation Therapy (RE-LY) trialStroke/systemic embolismGood renal functionHigh-risk patientsHistory of diabetesRE-LY trialPatient-level dataShared decision makingMedian followRenal functionHeart failureHeavier patientsMultivariable modelDabigatranIndividual patientsTreatment groupsIndividualized estimates